Synapse - Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy

Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy Journal Article

Authors:	Tamari, R.; Politikos, I.; Knorr, D. A.; Vardhana, S. A.; Young, J. C.; Marcello, L. T.; Doddi, S.; Devlin, S. M.; Ramanathan, L. V.; Pessin, M. S.; Dunn, E.; Palazzo, M.; Bravo, C. D.; Papanicolaou, G. A.; Kamboj, M.; Perales, M. A.; Chung, D. J.; Shah, G. L.
Article Title:	Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy
Abstract:	Cellular therapies including allogeneic hematopoietic cell transplant (allo-HCT) and autologous hematopoietic cell transplant (auto-HCT) and chimeric antigen receptor (CAR) T-cell therapy render patients severely immunocompromised for extended periods after therapy, and data on responses to COVID-19 vaccines are limited. We analyzed anti-SARS-CoV-2 spike IgG Ab (spike Ab) titers and neutralizing Ab among 217 recipients of cellular treatments (allo-HCT, n = 149; auto-HCT, n = 61; CAR T-cell therapy, n = 7). At 3 months after vaccination, 188 patients (87%) had positive spike Ab levels and 139 (77%) had positive neutralization activity compared with 100% for both in 54 concurrent healthy controls. Time from cellular therapy to vaccination and immune recovery post-cellular therapy were associated with response. Vaccination against COVID-19 is an important component of post-cellular therapy care, and predictors of quantitative and qualitative response are critical in informing clinical decisions about optimal timing of vaccines and the requirement for booster doses. SIGNIFICANCE: Identifying predictors of response to vaccination against SARS-CoV-2 in patients following cellular therapy is critical to managing this highly vulnerable patient population. To date, this is the most comprehensive study evaluating quantitative and qualitative responses to vaccination, providing parameters most predictive of response and potentially informing booster vaccination strategies.
Keywords:	immunogenicity; outcomes; recipients; clinical characteristics; hematological malignancies; covid-19
Journal Title:	Blood Cancer Discovery
Volume:	2
Issue:	6
ISSN:	2643-3230
Publisher:	American Association for Cancer Research
Date Published:	2021-11-01
Start Page:	577
End Page:	585
Language:	English
ACCESSION:	WOS:000715262200006
DOI:	10.1158/2643-3230.Bcd-21-0142
PROVIDER:	wos
PMCID:	PMC8580614
PUBMED:	34778798
Notes:	Article -- Source: Wos